Cardiopatía, embarazo y tratamiento anticoagulante

Pregnancy is a hypercoagulable state. Some women with cardiac disease and mechanical valve prosthesis are at increased risk of arterial thromboembolic phenomena. These women are maintained on oral anticoagulants and require effective permanent prophylaxis during pregnancy. The use of oral anticoagul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Braun J.,Sandra
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 1999
Materias:	Anticoagulants Coumarins Heart valve diseases Heart valve prosthesis Heparin Pregnanacy complications, medical
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871999001200001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98871999001200001
record_format	dspace
spelling	oai:scielo:S0034-988719990012000012000-04-05Cardiopatía, embarazo y tratamiento anticoagulanteBraun J.,Sandra Anticoagulants Coumarins Heart valve diseases Heart valve prosthesis Heparin Pregnanacy complications, medical Pregnancy is a hypercoagulable state. Some women with cardiac disease and mechanical valve prosthesis are at increased risk of arterial thromboembolic phenomena. These women are maintained on oral anticoagulants and require effective permanent prophylaxis during pregnancy. The use of oral anticoagulants during pregnancy is controversial because of the risks of embriopathy (Chondrodysplasia punctata) in fetuses who are exposed to coumarin between the 6th and 9th week of gestation, the risk of neurological disorders all through pregnancy, and a higher incidence of abortion and stillbirths. The exact incidence of these complications is unknown. Most of this information comes from North American reports, when much higher mean daily doses of coumarin were administered, and they were probably overemphasised2. Reports from Europe, Asia and our own, show that both embriopathy and central nervous system malformations are probably dose-related and that the risks of abnormality to the fetus are small3-8. The ACC Antithrombotic Consensus (1998) recommends the use of subcutaneous heparin all through pregnancy or until the 13th week of gestation. Heparin does not cross the placenta, however there is a higher risk of maternal bleeding, abortion and stillbirths. With the use of small dose of heparin and of therapeutic heparin doses there is a risk of prosthesis thrombosis. Anticoagulant treatment of patients with prosthetic heart valves during pregnancy remains controversial. Subcutaneous heparin prophylaxis is feasible but the use of well controlled oral anticoagulants appear to offer lower risks of maternal and fetal complications.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.127 n.12 19991999-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871999001200001es10.4067/S0034-98871999001200001
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anticoagulants Coumarins Heart valve diseases Heart valve prosthesis Heparin Pregnanacy complications, medical
spellingShingle	Anticoagulants Coumarins Heart valve diseases Heart valve prosthesis Heparin Pregnanacy complications, medical Braun J.,Sandra Cardiopatía, embarazo y tratamiento anticoagulante
description	Pregnancy is a hypercoagulable state. Some women with cardiac disease and mechanical valve prosthesis are at increased risk of arterial thromboembolic phenomena. These women are maintained on oral anticoagulants and require effective permanent prophylaxis during pregnancy. The use of oral anticoagulants during pregnancy is controversial because of the risks of embriopathy (Chondrodysplasia punctata) in fetuses who are exposed to coumarin between the 6th and 9th week of gestation, the risk of neurological disorders all through pregnancy, and a higher incidence of abortion and stillbirths. The exact incidence of these complications is unknown. Most of this information comes from North American reports, when much higher mean daily doses of coumarin were administered, and they were probably overemphasised2. Reports from Europe, Asia and our own, show that both embriopathy and central nervous system malformations are probably dose-related and that the risks of abnormality to the fetus are small3-8. The ACC Antithrombotic Consensus (1998) recommends the use of subcutaneous heparin all through pregnancy or until the 13th week of gestation. Heparin does not cross the placenta, however there is a higher risk of maternal bleeding, abortion and stillbirths. With the use of small dose of heparin and of therapeutic heparin doses there is a risk of prosthesis thrombosis. Anticoagulant treatment of patients with prosthetic heart valves during pregnancy remains controversial. Subcutaneous heparin prophylaxis is feasible but the use of well controlled oral anticoagulants appear to offer lower risks of maternal and fetal complications.
author	Braun J.,Sandra
author_facet	Braun J.,Sandra
author_sort	Braun J.,Sandra
title	Cardiopatía, embarazo y tratamiento anticoagulante
title_short	Cardiopatía, embarazo y tratamiento anticoagulante
title_full	Cardiopatía, embarazo y tratamiento anticoagulante
title_fullStr	Cardiopatía, embarazo y tratamiento anticoagulante
title_full_unstemmed	Cardiopatía, embarazo y tratamiento anticoagulante
title_sort	cardiopatía, embarazo y tratamiento anticoagulante
publisher	Sociedad Médica de Santiago
publishDate	1999
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871999001200001
work_keys_str_mv	AT braunjsandra cardiopatiaembarazoytratamientoanticoagulante
_version_	1718435893131345920

Cardiopatía, embarazo y tratamiento anticoagulante

Ejemplares similares